Current and future pharmacotherapy for female sexual dysfunction
In this Review, experts in the field discuss the treatments currently available for female sexual dysfunction and consider the new approaches that are currently in development.
In this Review, experts in the field discuss the treatments currently available for female sexual dysfunction and consider the new approaches that are currently in development.
In this Review, the authors discuss the causal role of current androgen deprivation therapy in prostate cancer progression, hormone refractoriness and double-null prostate cancer development. They highlight the underlying regulatory mechanisms by which androgen deprivation therapy elevates hepatocyte growth factor–hepatocyte growth factor receptor (HGF–MET) and WNT–β-catenin signalling, elevating exportin 1 (XPO1) and ribosomal protein activation to induce tumour aggressiveness, metastasis and double-null prostate cancer development.